These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20544247)

  • 1. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.
    Sangalli F; Moiola L; Bucello S; Annovazzi P; Rizzo A; Radaelli M; Vitello G; Grimaldi LM; Ghezzi A; Martinelli V; Comi G
    Neurol Sci; 2011 Jan; 31 Suppl 3():299-302. PubMed ID: 20544247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
    Totaro R; Lugaresi A; Bellantonio P; Danni M; Costantino G; Gasperini C; Florio C; Pucci E; Maddestra M; Spitaleri D; Lus G; Ardito B; Farina D; Rossi M; Di Carmine C; Altobelli E; Maccarone B; Casalena A; De Luca G; Travaglini D; Di Ioia M; Di Tommaso V; Fantozzi R; Ruggieri S; Provinciali L; De Riso S; Mundi C; Fuiani A; Galgani S; Ruggieri S; Maniscalco GT; Giuliani G; Cartechini E; Petretta V; Fratta M; Alfieri G; Gatto M; Carolei A;
    Int J Immunopathol Pharmacol; 2014; 27(2):147-54. PubMed ID: 25004826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.
    Prosperini L; Borriello G; Fubelli F; Marinelli F; Pozzilli C
    Neurol Sci; 2011 Jan; 31 Suppl 3():303-7. PubMed ID: 20535513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis.
    Melin A; Outteryck O; Collongues N; Zéphir H; Fleury MC; Blanc F; Lacour A; Ongagna JC; Berteloot AS; Vermersch P; de Sèze J
    J Neurol; 2012 Jun; 259(6):1215-21. PubMed ID: 22160375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
    Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
    Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
    J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
    Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.
    Alroughani R; Al Hashel J; Thussu A; Ahmed SF
    Med Princ Pract; 2013; 22(5):495-9. PubMed ID: 23797019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.
    Piehl F; Holmén C; Hillert J; Olsson T
    Neurol Sci; 2011 Jan; 31 Suppl 3():289-93. PubMed ID: 20556456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.